Norberto Tuason
Psychiatry · Los Angeles, CANPI 1841338555
Payments from drug & device makers
Across 515 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$967
- Vanda Pharmaceuticals Inc.$946
- Alkermes, Inc.$903
- Sunovion Pharmaceuticals Inc.$805
- plus $5K from 22 others
What the payments were for
- Food & beverage$11,187100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 52 | $1,583 |
| AbbVie(2 entities) | 47 | $1,023 |
| Teva Pharmaceuticals USA, Inc. | 53 | $967 |
| Vanda Pharmaceuticals Inc. | 33 | $946 |
| Alkermes, Inc. | 35 | $903 |
| Sunovion Pharmaceuticals Inc. | 43 | $805 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $788 |
| Otsuka America Pharmaceutical, Inc. | 25 | $595 |
| Lundbeck LLC | 34 | $559 |
| Neurocrine Biosciences, Inc. | 18 | $511 |
| Supernus Pharmaceuticals, Inc. | 26 | $382 |
| Indivior Inc. | 23 | $382 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $314 |
| Corium, LLC | 12 | $263 |
| E.r. Squibb & Sons, L.L.C. | 9 | $237 |
| Axsome Therapeutics, Inc. | 5 | $235 |
| Noven Therapeutics, LLC | 10 | $214 |
| Biogen | 1 | $121 |
| Merck | 5 | $80 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Avanir Pharmaceuticals, Inc. | 2 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Eisai Inc. | 2 | $30 |
| Bausch Health US, LLC | 2 | $27 |
| Noven Pharmaceuticals, Inc. | 1 | $23 |
| Neuronetics, Inc. | 2 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$923
- Fanapt$249
- VRAYLAR$247
- INVEGA SUSTENNA$237
- ARISTADA INITIO$231
- CAPLYTA$150
- REXULTI$144
- INGREZZA$133
- SPRAVATO$125
- QELBREE$125
- Auvelity$122
- LATUDA$122
- Zurzuvae$121
- COBENFY$120
- Austedo XR$116
How this compares
$11,199 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 16 | $46,595 |
| VraylarCariprazine Hcl | 12 | $16,451 |
| Lurasidone Hcl | 36 | $16,434 |
| Bupropion XlBupropion Hcl | 16 | $919 |
| Aripiprazole | 51 | $775 |
| Quetiapine Fumarate | 31 | $704 |
| Hydroxyzine Hcl | 96 | $642 |
| Buspirone Hcl | 91 | $365 |
| Olanzapine | 34 | $270 |
| Sertraline Hcl | 18 | $242 |
| Paroxetine Hcl | 27 | $137 |
| Topiramate | 15 | $105 |
| Fluoxetine Hcl | 22 | $105 |
| Lamotrigine | 22 | $93 |
| Trazodone Hcl | 21 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,583 | $46,59516 claims |
| AbbVieVraylar | $1,023 | $16,45112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Los Angeles
- Lon SchneiderLos Angeles$1.8M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.